NMDP BioTherapies and the NMDP BioTherapies Cord Blood Bank Alliance Introduce Optimal Cord Blood Units for Manufacture of NK Cell Therapies And Other Cord Derived Cell Therapies
2024年7月19日 - 1:37AM
ビジネスワイヤ(英語)
Leveraging the Power of the NMDP BioTherapies Cord Blood Bank
Alliance, Readily Accessible Cord Blood Units That Meet the
Criteria Established in Marin, et al in Nature Medicine for
Production of CAR-NK Cells
NMDP BioTherapiesSM (formerly known as the Be The Match
BioTherapies), a leader in cell and gene therapy development
support, and the NMDP BioTherapies Cord Blood Bank Alliance (CBBA),
a partnership between NMDP BioTherapies and nine public cord blood
banks, are making available pre-identified cord blood units that
are optimized for manufacture of cord-derived cell therapies, and
in particular cord-derived NK cell therapies. The identification
and supply of these units leverages the over 200,000 cord blood
units in the inventory of the CBBA as well as NMDP BioTherapies’
cord unit search platform, through which individual cord blood
units that meet specific requirements can be rapidly
identified.
“It’s already known that cord blood units can be an excellent
source of starting material for manufacture of cell and gene
therapies. Dr. Katayoun Rezvani’s presentation at ASH in December
2023 and subsequent Nature Medicine paper advanced the field
substantially, identifying cord blood unit attributes that
correlated with excellent manufacturing and clinical outcomes for
therapeutically administered cord blood derived CAR-NK cells,” said
Joy Aho, Director of Product Management at NMDP BioTherapies.
“These units can be difficult to find, but through our partnership
with the members of the Cord Blood Bank Alliance, we are able to
quickly search, identify, and make available units that fit Dr.
Rezvani’s criteria, making it easier for cell and gene therapy
industry partners to further advance the field and pursue our
shared mission of improving outcomes for patients.”
The CBBA brings together leading cord blood banks with decades
of experience managing the development, production and distribution
of allogeneic products in a regulated environment. Initially, the
CBBA included eight NMDP member banks that have demonstrated
commitment to serving the needs of patients and providing high
quality cord blood units for the development and commercialization
of emerging cell and gene therapies.
“We are excited to help advance the manufacture of high quality
and clinically effective cell and gene therapies,” said Jill
Thomas, Director of Operations, Bloodworks Bio. “The field is still
early in its development, and the cord blood unit criteria shared
in the Nature Medicine paper are a compelling advance, one that
should translate into significant positive clinical impact for
patients receiving cord blood derived NK cell therapies and
potentially other types of cell therapies as well.”
Specific cord blood units that meet the Rezvani criteria have
been identified using NMDP BioTherapies’ cord search platform, and
member CBBA banks have set the units aside for rapid delivery after
orders are placed through the NMDP BioTherapies website
(https://nmdpbiotherapies.com/cord-blood/). All of the units were
cryopreserved less than 24 hours from collection, feature low nRBC
counts, meet CFR 1271 requirements, and are commercially
consented.
About NMDP BioTherapies
NMDP BioTherapies is the only cell and gene therapy solutions
provider with customizable services to support the end-to-end cell
therapy supply chain. Backed by the industry-leading experience of
NMDP℠ and a research partnership with the CIBMTR® (Center for
International Blood and Marrow Transplant Research®), the
organization designs solutions that advance the development of cell
and gene therapies across the globe.
NMDP BioTherapies is dedicated to accelerating patient access to
life-saving cell and gene therapies by providing high-quality
cellular source material from the NMDP Registry℠, the world’s most
diverse registry of more than 7 million potential blood stem cell
donors. Through established relationships with apheresis, marrow
collection, and transplant centers worldwide, the organization
develops, onboards, trains, and manages expansive collection
networks to advance cell therapies. NMDP BioTherapies uses a proven
infrastructure consisting of regulatory compliance and managed
logistics experts and cell therapy supply chain case managers to
successfully transport and deliver regulatory-compliant life-saving
therapies across the globe. Through the CIBMTR, NMDP extends
services beyond the cell therapy supply chain to include long-term
follow-up tracking for FDA-approved CAR-T therapies.
For more information, follow NMDP BioTherapies on LinkedIn or
Twitter.
About Bloodworks Northwest
Bloodworks Northwest provides a lifesaving blood supply and
services to 95% of Western Washington and Oregon hospitals. Since
1944, Bloodworks has served the Pacific Northwest as a local,
nonprofit, independent, volunteer-supported and community-based
blood center and research institute. Our Bloodworks Bio division
offers a complete ecosystem of blood-based biological products and
cellular therapy to support global biomedical research and
discoveries. As experts in all things blood, Bloodworks Bio’s
vision is to accelerate discoveries by providing comprehensive
blood products, manufacturing services, and quality support for our
biomedical and research partners in support of their research,
clinical and commercial programs. Bloodworks Research Institute,
the research division of Bloodworks Northwest, performs
leading-edge research in blood biology, transfusion medicine, blood
storage and treatment of blood disorders. Patients with traumatic
injuries, undergoing surgeries or organ transplantation, or
receiving treatment for cancer and blood disorders all depend on
its services, expertise, laboratories and research. For more
information, visit bloodworksbio.org.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240718060474/en/
NMDP BioTherapies Media Contacts: Matt Mayr
Info@NMDPbiotherapies.com (800) 471-4431
Bloodworks Media Contacts: Karen Kirby karenk@bloodworksnw.org
206-689-6359